Webcast Alert: Oscient Pharmaceuticals to Present at BIO CEO & Investor Conference

Oscient Pharmaceuticals Corporation (Nasdaq:OSCI) will participate in the BIO CEO & Investor Conference on Wednesday, February 15, 2006 in New York City. The Company’s President and CEO, Steven Rauscher, will provide an overview of the Company including details on the recent sublicense of FACTIVE(R) (gemifloxacin mesylate) tablets in Mexico to Pfizer S.A. de C.V. and the acquisition of expanded worldwide rights for the Company’s lead clinical candidate, Ramoplanin.

 What:    Oscient Pharmaceuticals at BIO CEO & Investor Conference  When:    February 15, 2006 at 11:30 am Eastern Time  How:     The webcast will be available through the Company’s website           at www.oscient.com.  Contact: Christopher Taylor, 781-398-2466 or Sarah Emond, 781-398-2544 

An archive of the webcast will also be available for three months.

About Oscient Pharmaceuticals

Oscient Pharmaceuticals Corporation is a biopharmaceutical company committed to the clinical development and commercialization of novel therapeutics to address unmet medical needs. The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic bronchitis and mild to moderate community-acquired pneumonia. In addition to the oral tablet form, Oscient is developing an investigational FACTIVE intravenous formulation for use in hospitalized patients. The Company is also promoting Auxilium Pharmaceuticals’ TESTIM(R) 1% testosterone gel to primary care physicians in the U.S. Oscient has a novel antibiotic candidate, Ramoplanin, in advanced clinical development for the treatment of Clostridium difficile-associated disease (CDAD).